Meloxicam is available in several dosage strengths, commonly including 5 mg, 10 mg, and 15 mg [1]. These strengths are prescribed by healthcare professionals based on the individual patient's needs and the condition being treated [2].
How is Meloxicam Typically Dosed?
The typical starting dose for meloxicam in adults for osteoarthritis is 5 mg or 7.5 mg once daily [3]. For rheumatoid arthritis, the starting dose is often 7.5 mg once daily, which can be increased to 15 mg once daily if needed [3]. For juvenile idiopathic arthritis in children aged 2 years and older, doses vary based on weight, typically ranging from 0.05 mg/kg to 0.125 mg/kg once daily, not to exceed 7.5 mg per day [3].
What Are the Different Forms of Meloxicam?
Meloxicam is available in oral forms, including tablets and capsules [4]. There is also an oral suspension formulation [4]. Injectable forms are also available for specific medical settings [4].
What Are the Side Effects Associated with Meloxicam?
Common side effects of meloxicam can include stomach pain, nausea, vomiting, diarrhea, constipation, gas, and dizziness [5]. More serious side effects may involve signs of bleeding in the stomach or intestines, such as black, tarry stools or vomiting blood [5]. Other serious concerns can include heart problems, kidney problems, and allergic reactions [5].
What is Meloxicam Used For?
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation associated with various conditions [6]. It is commonly prescribed for osteoarthritis and rheumatoid arthritis in adults [3]. It is also used to treat juvenile idiopathic arthritis in children [3].
What is the Patent Status for Meloxicam?
Meloxicam was first patented by Boehringer Ingelheim [7]. As a widely used medication, its primary patents have long expired, allowing for the production of generic versions [8]. DrugPatentWatch.com tracks patent information for drugs, including expiry dates and any related litigation [9]. While original patents expire, new patents related to formulations or methods of use can be issued [9].